|Candidate & Indication||Research Stage|
|SYN-005 Pertussis (Whooping Cough)||
Discovery Phase complete
Preclinical Phase in progress
|SYN-200 Phenylketonuria (PKU)||
Discovery Phase in progress
Preclinical Phase not started
Through our August 2012 Exclusive Channel Collaboration (ECC) with Intrexon Corporation (NYSE: XON) and academic researchers at The University of Texas at Austin (UT Austin), we are developing SYN-005, a combination of two humanized antibodies that includes hu1B7, for the treatment of critically ill infants with Pertussis. In addition, UT Austin was awarded a grant from the Gates Foundation to generate preclinical proof-of-concept data to test the hypothesis that hu1B7 antibody administration at birth may also have a role in the prevention of Pertussis. Jennifer Maynard, Ph.D., the principal investigator of the grant at UT Austin, will test this hypothesis by using our hu1B7 antibody.
Through our August 2015 ECC with Intrexon Corporation, we are pursuing the development and commercialization of novel biotherapeutics for the treatment of patients with phenylketonuria (PKU), a serious and debilitating metabolic disorder. Through the ECC, we plan to utilize Intrexon's ActoBiotics™ platform which is a proprietary method of delivering therapeutic protein and peptides to the gastrointestinal (GI) tract through food-grade microbes.